Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVB-101 intrathalamic gene therapy study in frontotemporal dementia with progranulin mutations
NL-OMON53802Phase 2Withdrawn
- Sponsor
- AviadoBio
- Start
- Nov 2022
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AVB-101 in frontotemporal dementia (FTD), sponsored by AviadoBio. Primary endpoints: Adverse events and serious adverse events, Vital signs, ECG, and examinations and 5 more. Planned start Nov 2022; status: withdrawn.
02
Drugs
AVB-101
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON53802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53802.